Xinhua Lande (08106) plans to issue 9.835 million shares for private investment from Guangdong, Hong Kong, and Macau. Trading will resume on February 13.

16:56 12/02/2026

Chemical Rand (08106) announced that on February 12, 2026, the company and Guangdong-Hong Kong-Macao private investment limited company entered into a supplemental agreement to the subscription agreement, adjusting the number of H shares subscribed by the subscriber from 12.73 million H shares to 9.835 million H shares. Apart from the aforementioned change, all other terms and conditions of the subscription agreement with the subscriber remain unchanged. The company has applied for the resumption of H shares trading on the GEM of the Stock Exchange of Hong Kong Limited starting from 9:00 a.m. on February 13, 2026.

XINHUA LANDE (08106) announced on February 12, 2026 that the company has entered into a supplementary agreement with Guangdong-Hong Kong-Macau Private Investment Limited to adjust the number of H shares subscribed by the subscriber from 12.73 million shares to 9.835 million shares. Apart from the aforementioned change, all other terms and conditions of the subscription agreement remain unchanged. The company has applied to resume the trading of H shares on the GEM of the Hong Kong Stock Exchange starting from 9:00 am on February 13, 2026.

HC TECH GP (01116): Liu Guoxiong appointed as Chief Independent Non-Executive Director.

Sanofi (SNY.US) suddenly changes its leader: research and development "mute fire" becomes a "life-saving talisman", Merck & Co., Inc. executive takes over urgently.

PW MEDTECH (01358): Sichuan Ruijian Medical's net profit attributable to the parent company in 2025 is expected to be approximately 151 million yuan, a year-on-year increase of 17.99%.

HC TECH GP (01116): Liu Guoxiong appointed as Chief Independent Non-Executive Director.

Sanofi (SNY.US) suddenly changes its leader: research and development "mute fire" becomes a "life-saving talisman", Merck & Co., Inc. executive takes over urgently.

PW MEDTECH (01358): Sichuan Ruijian Medical's net profit attributable to the parent company in 2025 is expected to be approximately 151 million yuan, a year-on-year increase of 17.99%.